An overview of foot infections in diabetes

Diabetes Technology and Therapeutics

Volumn 13, Issue 9, 2011, Pages 951-957

  Armstrong, David G ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CEFTAZIDIME; CEFTOBIPROLE; CEFUROXIME; CIPROFLOXACIN; COTRIMOXAZOLE; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERTAPENEM; ICLAPRIM; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; ORITAVANCIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; TELAVANCIN; TIGECYCLINE; VANCOMYCIN;

AEROBIC BACTERIUM; ANAEROBIC BACTERIUM; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BACTERIUM ISOLATE; COMORBIDITY; DIABETES MELLITUS; DIABETIC FOOT; DIABETIC PATIENT; DISEASE SEVERITY; FOOT DISEASE; GASTROINTESTINAL SYMPTOM; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEMATOLOGIC DISEASE; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; OSTEOMYELITIS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; UNSPECIFIED SIDE EFFECT; WOUND HEALING IMPAIRMENT; WOUND INFECTION;

ANTI-BACTERIAL AGENTS; DIABETIC FOOT; FOOT; HUMANS; INFECTION; LIMB SALVAGE; RECURRENCE; SEVERITY OF ILLNESS INDEX;

EID: 80052060286     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2011.0007     Document Type: Review

References (57)

1. Centers for Disease Control and Prevention: National Diabetes Fact Sheet, 2007. Atlanta: Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, 2007.
2. Roglic G, Unwin N, Bennett PH, Mathers C, Tuomilehto J, Nag S, Connolly V, King H: The burden and mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care 2005;28:2130-2135. (Pubitemid 41242456)
3. Wild S, Roglic G, Green A, Sicree R, King H: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-1053. (Pubitemid 38579764)
4. Iversen MM, Tell GS, Riise T, Hanestad BR, Østbye T, Graue M, Midthjell K: A history of foot ulcer increases mortality among persons with diabetes: a 10-year follow-up of the Nord-Trøndelag Health Study, Norway. Diabetes Care 2009;32:2193-2199.
5. Lavery LA, Armstrong DG, Peters EJ, Lipsky BA: Probe-to-bone test for diagnosing diabetic foot osteomyelitis: reliable or relic? Diabetes Care 2007;30:270-274. (Pubitemid 46198329)
6. Chow I, Lemos EV, Einarson TR: Management and prevention of diabetic foot ulcers and infections: a health economic review. Pharmacoeconomics 2008;26:1019-1035.
7. Armstrong DG, Lipsky BA: Diabetic foot infections: stepwise medical and surgical management. Int Wound J 2004;1: 123-132.
8. Jeffcoate WJ, Lipsky BA, Berendt AR, Cavanagh PR, Bus SA, Peters EJ, van Houtum WH, Valk GD, Bakker K; International Working Group on the Diabetic Foot: Unresolved issues in the management of ulcers of the foot in diabetes. Diabet Med 2008;25:1380-1389.
9. Winkley K, Stahl D, Chalder T, Edmonds ME, Ismail K: Quality of life in people with their first diabetic foot ulcer: a prospective cohort study. J Am Podiatr Med Assoc 2009;99: 406-414.
10. th Malvern Diabetic Foot Meeting. Int J Low Extrem Wounds 2008;7: 235-238.
11. Kosinski MA, Joseph WS: Update on the treatment of diabetic foot infections. Clin Podiatr Med Surg 2007;24:383-396. (Pubitemid 47001682)
12. Howell-Jones RS, Wilson MJ, Hill KE, Howard AJ, Price PE, Thomas DW: A review of the microbiology, antibiotic usage and resistance in chronic skin wounds. J Antimicrob Che-mother 2005;55:143-149. (Pubitemid 40331137)
13. Lipsky BA, Berendt AR, Deery HG, Embil JM, Joseph WS, Karchmer AW, LeFrock JL, Lew DP, Mader JT, Norden C, Tan JS; Infectious Diseases Society of America: Diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2004;39:885-910. (Pubitemid 39328144)
14. Lavery LA, Armstrong DG, Murdoch DP, Peters EJG, Lipsky BA: Validation of the Infectious Diseases Society of America's diabetic foot infection classification system. Clin Infect Dis 2007;44:562-565. (Pubitemid 46233260)
15. Apelqvist J, Bakker K, van Houtum WH, Schaper NC; International Working Group on the Diabetic Foot (IWGDF) Editorial Board: Practical Guidelines on the management and prevention of diabetic foot. Diabetes Metab Res Rev 2008;24(Suppl 1):S181-S187. (Pubitemid 351802788)
16. Newman LG, Waller J, Palestro CJ, Schwartz M, Klein MJ, Hermann G, Harrington E, Harrington M, Roman SH, Stagnaro-Green A: Unsuspected osteomyelitis in diabetic foot ulcers. Diagnosis and monitoring by leukocyte scanning with indium In 111 oxyquinoline. JAMA 1991;266: 1246-1251.
17. Grayson ML, Gibbons GW, Balogh K, Levin E, Karchmer AW: Probing to bone in infected pedal ulcers: a clinical sign of underlying osteomyelitis in diabetic patients. JAMA 1995;273:721-723.
18. Butalia S, Palda VA, Sargeant RJ, Detsky AS, Mourad O: Does this patient with diabetes have osteomyelitis of the lower extremity? JAMA 2008;299:806-813. (Pubitemid 351281574)
19. Gerding, DN: Foot infections in diabetic patients: the role of anaerobes. Clin Infect Dis 1995;20(Suppl 2):S283-S288.
20. Vardakas KZ, Horianopoulou M, Falagas ME: Factors associated with treatment failure in patients with diabetic foot infections: an analysis of data from randomized controlled trials. Diabetes Res Clin Pract 2008;80:344-351.
21. Majcher-Peszynska J, Haase G, Sass M, Mundkowski R, Pietsch A, Klammt S, Schareck W, Drewelow B: Pharmaco-kinetics and penetration of linezolid into inflamed soft tissue in diabetic foot infections. Eur J Clin Pharmacol 2008;64: 1093-1100.
22. Citron DM, Goldstein EJ, Merriam CV: Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents. J Clin Microbiol 2007;45; 2819-2828. (Pubitemid 47417321)
23. Yates CJ, May K, Hale T, Allard B, Rowlings N, Freeman A, Harrison J, McCann J, Wraight P: Wound chronicity, inpa-tient care, and chronic kidney disease predispose to MRSA infection in diabetic foot ulcers. Diabetes Care 2009;32: 1907-1909.
24. Sotto A, Bouziges N, Jourdan N, Richard JL, Lavigne JP: In vitro activity of tigecycline against strains isolated from diabetic foot ulcers. Pathol Biol (Paris) 2007;55:398-406. (Pubitemid 350017721)
25. Shankar EM, Mohan V, Premalatha G: Bacterial etiology of diabetic foot infections in South India. Eur J Intern Med 2005;16:567-570. (Pubitemid 41728210)
26. Richard JL, Sotto A, Jourdan N, Combescure C, Vannereau D, Rodier M, Lavigne JP; N̂imes University Hospital Working Group on the Diabetic Foot (GP30): Risk factors and healing impact of multidrug-resistant bacteria in diabetic foot ulcers. Diabetes Metab 2008;34:363-369.
27. Ge Y, MacDonald D, Hait H, Lipsky B, Zasloff M, Holroyd K: Microbiological profile of infected diabetic foot ulcers. Diabet Med 2002;19:1032-1034. (Pubitemid 35471974)
28. Gadepalli R, Dhawan B, Sreenivas V:A clinico-microbiological study of diabetic foot ulcers in an Indian tertiary care hospital. Diabetes Care 2006;29:1727-1732. (Pubitemid 44156621)
29. Lipsky BA: New developments in diagnosing and treating diabetic foot infections. Diabetes Metab Res Rev 2008: 24(Suppl 1):S66-S71. (Pubitemid 351802774)
30. Louie TJ, Bartlett JG, Tally FP, Gorbach SL: Aerobic and anaerobic bacteria in diabetic foot ulcers. Ann Intern Med 1976;85:461-463.
31. Sapico FL, Canawati HN, Witte JL, Montgomerie JZ, Wagner FW, Bessman AN: Quantitative aerobic and anaerobic bacteriology of infected diabetic feet. J Clin Microbiol 1980;12:413-420. (Pubitemid 10054036)
32. Hunt JA: Foot infections in diabetes are rarely due to a single microorganism. Diabet Med 1992;9:749-752.
33. Lipsky BA: Evidence-based antibiotic therapy of diabetic foot infections. FEMS Immunol Med Microbiol 1999;26:267-276.
34. Lipsky BA, Armstrong DG, Citron DM, Tice AD, Morgen-stern DE, Abramson MA: Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP); prospective, randomized, controlled, double-blinded multi-centre trial. Lancet 2005;366:1695-1703. (Pubitemid 41587448)
35. Tentolouris N, Jude EB, Smirnof I, Knowles EA, Boulton AJM: Methicillin-resistant Staphylococcus aureus: an increasing problem in a diabetic foot clinic. Diabet Med 1999;16: 767-771. (Pubitemid 29459276)
36. Dang CN, Prasad YDM, Boulton AJM, Jude EB: Methicillin-resistant Staphylococcus aureus in the diabetic foot clinic: a worsening problem. Diabet Med 2003;20:159-161. (Pubitemid 36269659)
37. Lagace-Wiens PRS, Ormiston D, Nicolle LE, Hilderman T, Embil J: The diabetic foot clinic: not a significant source of acquisition of methicillin-resistant Staphylococcus aureus. Am J Infect Control 2009;37:587-589.
38. Armstrong DG, Lipsky BA: Advances in the treatment of diabetic foot infections. Diabetes Technol Ther 2004;6:166-177.
39. Nelson EA, O'Meara S, Golder S, Dalton J, Craig D, Iglesias C; DASIDU Steering Group: Systematic review of antimicrobial treatments for diabetic foot ulcers. Diabet Med 2006;23:348-359.
40. Lipsky BA: A report from the international consensus on diagnosing and treating the infected diabetic foot. Diabetes Metab Res Rev 2004;20(Suppl 1):S68-S77. (Pubitemid 38714340)
41. Lipsky BA, Itani K, Norden C; Linezolid Diabetic Foot Infections Study Group: Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavula- nate. Clin Infect Dis 2004;38:17-24. (Pubitemid 38045868)
42. Omar NS, El-Nahas MR, Gray J: Novel antibiotics for the management of diabetic foot infections. Int J Antimicrob Agents 2008;31:411-419.
43. Stein GE, Schooley S, Peloquin CA, Missavage A, Havlichek DH: Linezolid tissue penetration and serum activity against strains of methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility in diabetic patients with foot infections. J Antimicrob Chemother 2007;60:819-823. (Pubitemid 47434261)
44. Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT: In vitro activity of ceftobiprole against aerobic and anaerobic strains isolated from diabetic foot infections. Antimicrob Agents Chemother 2006;50:3959-3962. (Pubitemid 44684928)
45. Deresinski SC: The efficacy and safety of a ceftobiprole in the treatment of complicated skin and skin structure infections: evidence from 2 clinical trials. Diagn Microbiol Infect Dis 2008;61:103-109. (Pubitemid 351509757)
46. Lipsky BA, Stoutenburgh U: Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J Antimicrob Chemother 2005;55:240-245. (Pubitemid 40331152)
47. Seaton RA: Daptomycin: rationale and role in the management of skin and soft tissue infections. J Antimicrob Che-mother 2008;62(Suppl 3):iii15-iii23.
48. Goldstein EJ, Citron DM, Warren YA, Tyrrell KL, Merriam CV, Fernandez HT: In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic gram-positive isolates recovered from diabetic foot infections. Antimicrob Agents Chemother 2006;50:2875-2879. (Pubitemid 44198720)
49. Lentino JR, Narita M, Yu VL: New antimicrobial agents as therapy for resistant gram-positive cocci. Eur J Clin Micro-biol Infect Dis 2008;27:3-15. (Pubitemid 350197870)
50. Krievins D, Brandt R, Hawser S, Hadvary P, Islam K: Mul-ticenter, randomized study of the efficacy and safety of intravenous iclaprim in complicated skin and skin structure infections. Antimicrob Agents Chemother 2009;53: 2834-2840.
51. Laue H, Weiss L, Bernardi A, Hawser S, Lociuro S, Islam K: In vitro activity of the novel diaminopyrimidine, iclaprim, in combination with folate inhibitors and other antimicrobials with different mechanisms of action. J Antimicrob Che-mother. 2007;60:1391-1394. (Pubitemid 350168340)
52. Lew DP, Waldvogel FA: Use of quinolones in osteomyelitis and infected orthopaedic prosthesis. Drugs 1999;58(Suppl 2):85-91. (Pubitemid 29500093)
53. Lipsky BA, Giordano P, Choudhri S, Song J: Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate. J Antimicrob Chemother 2007;60: 370-376. (Pubitemid 47243888)
54. Fritsche TR, Sader HS, Jones RN: Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004). Diagn Mi-crobiol Infect Dis 2007;58:19-26. (Pubitemid 46694276)
55. Edmiston CE, Krepel CJ, Seabrook GR, Somberg LR, Nakeeb A, Cambria RA, Towne JB: In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections. Antimicrob Agents Chemother 2004;48:1012-1016. (Pubitemid 38280357)
56. U.S. Food and Drug Administration. FDA Drug Safety Communication: Increased Risk of Death with Tygacil (Tigecycline) Compared to Other Antibiotics Used to Treat Similar Infections. www.fda.gov/Drugs/DrugSafety/ucm 224370.htm (accessed September 9, 2010).
57. Allington DR, Rivey MP: Quinupristin/dalfopristin: a therapeutic review. Clin Ther 2001;23:24-44. (Pubitemid 32113620)